Abstract
Eosinophils can regulate local and systemic inflammation, and their presence in higher numbers appears to play an important role in the pathology of various atopic and inflammatory diseases. Eosinophil maturation, recruitment, and survival depend on several cytokine regulators, including interleukin (IL)-5, IL-4, and IL-13 as well as growth factors such as GM-CSF. Over the last decade, the approach to treating eosinophilic diseases has changed greatly. A number of biologic modulators have been developed to target eosinophilic inflammatory pathways, and their usage has resulted in variable clinical improvement in the treatment of eosinophilicassociated conditions. Novel targeted therapies that are safe and effective for treating these disorders are being investigated. This review summarizes the clinical use of biologic agents that have been studied in clinical trials or approved for treating eosinophilic diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 252-272 |
| Number of pages | 21 |
| Journal | Clinical Reviews in Allergy and Immunology |
| Volume | 50 |
| Issue number | 2 |
| DOIs | |
| State | Published - Aug 17 2016 |
Keywords
- Asthma
- Biologics
- Churg-Strauss syndrome
- Eosinophilic diseases
- Eosinophilic esophagitis
- Eosinophilic granulomatosis with polyangiitis
- Eosinophils
- Hypereosinophilic syndrome
- Monoclonal antibodies
- Nasal polyposis
Fingerprint
Dive into the research topics of 'Biological modulators in eosinophilic diseases'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver